Preliminary report on postmenopausal endometrial hyperplasia treatment with Danazol: histological and endocrinological aspects
Danazol treatment of postmenopausal endometrial hyperplasia caused regression of hyperplasia and suggested inhibition of peripheral sulfatase activity, thereby reducing active unconjugated estrogens.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (5)
- [Medical treatment of idiopathic menorrhagia] 2008
- Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study 2004
- Danazol enhances Fas-mediated apoptosis in human endometrial epithelial cells within normal physiology 1998
- Action of danazol on the conversion of estrone sulfate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells 1993
- Preliminary report on the use of danazol in the treatment of endometrial adenomatous hyperplasia 1988
Source provenance
- europepmc
- last seen: 2026-10-13T06:10:10.580696+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:40:31.801315+00:00